Page 15 - linda_borst

REFERENCES

1 Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J Exp Med
183, 725-729, doi:10.1084/jem.183.3.725 (1996).
2 Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer
antigens. Immunity 10, 281-287, doi:10.1016/s1074-7613(00)80028-x (1999).
3 Old, L. J. Cancer vaccines 2003: opening address. Cancer Immun 3 Suppl 2, 1 (2003).
4 Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. & Chen, Y. T. Cancer/testis antigens: an
expanding family of targets for cancer immunotherapy. Immunol Rev 188, 22-32, doi:10.1034/
j.1600-065x.2002.18803.x (2002).
5 Ilyas, S. & Yang, J. C. Landscape of Tumor Antigens in T Cell Immunotherapy. J Immunol 195, 5117- Chapter 1
5122, doi:10.4049/jimmunol.1501657 (2015).
6 Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, Adaptive, and Acquired Resistance
to Cancer Immunotherapy. Cell 168, 707-723, doi:10.1016/j.cell.2017.01.017 (2017).
7 Coley, W. B. The Treatment of Sarcoma with the Mixed Toxins of Erysipelas and Bacillus Prodigiosus.
The Boston Medical and Surgical Journal 158, 175-182, doi:10.1056/nejm190802061580601
(1908).
8 Coley, W. B. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins
of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 3, 1-48,
doi:10.1177/003591571000301601 (1910).
9 Ehrlich, P. & Dale, S. H. H. The Collected Papers of Paul Ehrlich. Vol. II (Pergamon Press, 2013).
10 Ehrlich, P. Ueber den jetzigen Stand der Karzinomforschung. (1908).
11 Burnet, M. Cancer; a biological approach. I. The processes of control. Br Med J 1, 779-786,
doi:10.1136/bmj.1.5022.779 (1957).
12 Thomas, L. & Lawrence, H. Cellular and humoral aspects of the hypersensitive states. New York:
Hoeber-Harper, 529-532 (1959).
13 Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70, doi:10.1016/s0092-
8674(00)81683-9 (2000).
14 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674,
doi:10.1016/j.cell.2011.02.013 (2011).
15 Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from
immunosurveillance to tumor escape. Nat Immunol 3, 991-998, doi:10.1038/ni1102-991 (2002).
16 Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and
immunoediting. Immunity 21, 137-148, doi:10.1016/j.immuni.2004.07.017 (2004).
17 Pettit, S. J., Seymour, K., O’Flaherty, E. & Kirby, J. A. Immune selection in neoplasia: towards a
microevolutionary model of cancer development. Br J Cancer 82, 1900-1906, doi:10.1054/
bjoc.2000.1206 (2000).
18 Smyth, M. J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous
lymphoma. J Exp Med 192, 755-760, doi:10.1084/jem.192.5.755 (2000).
19 Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape
tumour immunogenicity. Nature 410, 1107-1111, doi:10.1038/35074122 (2001).
20 Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature
450, 903-907, doi:10.1038/nature06309 (2007).
21 Seliger, B., Maeurer, M. J. & Ferrone, S. Antigen-processing machinery breakdown and tumor
growth. Immunol Today 21, 455-464, doi:10.1016/s0167-5699(00)01692-3 (2000).

GENERAL INTRODUCTION 13